Sickle cell disease strategies and priorities - Authors' reply

Affiliations

¹ Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London W2 1PG, UK. Electronic address: f.piel@imperial.ac.uk.
² Department of Pediatrics, Vanderbilt-Meharry Center of Excellence for Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, TN, USA.
³ Department of Haematology and Blood Transfusion, College of Health Sciences and Centre of Excellence for Sickle Cell Disease Research and Training, University of Abuja, Abuja, Nigeria.

Comment

Frédéric B Piel et al. Lancet Haematol. 2023 Oct.

. 2023 Oct;10(10):e795.

doi: 10.1016/S2352-3026(23)00269-7.

¹ Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London W2 1PG, UK. Electronic address: f.piel@imperial.ac.uk.
² Department of Pediatrics, Vanderbilt-Meharry Center of Excellence for Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, TN, USA.
³ Department of Haematology and Blood Transfusion, College of Health Sciences and Centre of Excellence for Sickle Cell Disease Research and Training, University of Abuja, Abuja, Nigeria.

No abstract available

Conflict of interest statement

We declare no competing interests.

Sickle cell disease strategies and priorities.
Bonnechère B. Bonnechère B. Lancet Haematol. 2023 Oct;10(10):e793-e794. doi: 10.1016/S2352-3026(23)00266-1. Lancet Haematol. 2023. PMID: 37793765 No abstract available.
Sickle cell disease strategies and priorities.
Luzzatto L. Luzzatto L. Lancet Haematol. 2023 Oct;10(10):e794-e795. doi: 10.1016/S2352-3026(23)00267-3. Lancet Haematol. 2023. PMID: 37793766 No abstract available.